AN2 Therapeutics Inc
ANTX
Company Profile
Business description
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
Contact
1800 El Camino Real
Suite D
Menlo ParkCA94027
USAT: +1 650 331-9090
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
36
Stocks News & Analysis
stocks
The best way to get rich and retire early
This goes through the different options including shares, property and business ownership and declares a winner, as well as outlining the mindset needed to earn enough to never have to work again.
stocks
Investors overly negative on cheap ASX share
We cut our fair value by 26% but the market has overreacted.
stocks
Overvalued US AI play reports earnings
Strong earnings with high projected growth but price is too rich.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,096.20 | 77.60 | 0.86% |
| CAC 40 | 8,108.82 | 12.25 | -0.15% |
| DAX 40 | 24,322.69 | 38.72 | 0.16% |
| Dow JONES (US) | 48,355.34 | 7.34 | -0.02% |
| FTSE 100 | 9,889.93 | 23.96 | 0.24% |
| HKSE | 25,774.14 | 27.63 | -0.11% |
| NASDAQ | 23,406.46 | 22.37 | -0.10% |
| Nikkei 225 | 50,412.87 | 10.48 | 0.02% |
| NZX 50 Index | 13,517.73 | 9.43 | 0.07% |
| S&P 500 | 6,878.13 | 0.36 | -0.01% |
| S&P/ASX 200 | 8,795.70 | 78.80 | 0.90% |
| SSE Composite Index | 3,919.98 | 2.61 | 0.07% |